MedTrace Logo

Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma

NCT04571229 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-11

No results posted yet for this study

Summary

This expanded access protocol will allow access to treatment with L-MTP-PE for people with osteosarcoma. L-MTP-PE is an investigational drug that has not been approved by the FDA to treat any condition, including osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system kill cancer cells.

Conditions

Interventions

DRUG

L-MTP-PE

L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.

Sponsors & Collaborators

Principal Investigators

  • Emily Slotkin, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04571229 on ClinicalTrials.gov